Clinical and Experimental Allergy最新文献

{"title":"Development and Validation of a Prognostic Clinical Risk Score for Subsequent Atopic Dermatitis Risk.","authors":"Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev, Oliver Sanders, Shira Benor, Michael Brandwein","doi":"10.1111/cea.14567","DOIUrl":"https://doi.org/10.1111/cea.14567","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Patients Into Programmes to Address the Allergy Knowledge Practice Gap","authors":"John O. Warner,&nbsp;Sophie Jacoba Irma Maria Spitters","doi":"10.1111/cea.14563","DOIUrl":"10.1111/cea.14563","url":null,"abstract":"<p>There is a wide gap between the first publication of new treatments with efficacy and their successful application in clinical practice. In many respects, the management of allergic diseases is a good exemplar of the knowledge/practice gap. It was assumed that systematic reviews and publication of guidelines would ensure timely delivery of effective care, but this has not proved to be the case. While there are many reasons to explain shortcomings in healthcare delivery, the lack of patient and carer involvement in the planning of research, evidence review, guideline development and guideline implementation is most compelling. To achieve adherence to evidence-based guidelines consistently across all levels of the health service requires the implementation of integrated care with clear pathways through which patients can navigate. Quality improvement methodology could be employed to plan and implement integrated care pathways (ICPs). There is evidence that ICPs achieve improved outcomes for acute hospital-based interventions, but less work has focussed on long-term conditions where more diverse agencies are involved. At all stages, stakeholder representation from the full range of healthcare professionals, patients, their families, social services, education, local government and employers must be involved. In this article we review the step-wise and iterative process by which knowledge is implemented into practice to improve patient experience and outcomes We argue how this process can benefit from the involvement of patients and their carers as equal partners, and we discuss how different initiatives have involved patients with allergic diseases. There currently is a gap in evidence that links patient involvement to improved outcomes. We recommend the use of the Core Outcome Sets (COS) and Patient Reported Experience Measures (PREMS) which have been developed for allergic diseases to monitor the effects of implementation research and the impact of patient and carer involvement on outcomes.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 10","pages":"723-733"},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional Considerations of Plant-Based Diets for People With Food Allergy","authors":"Jennifer L. P. Protudjer,&nbsp;Franziska Roth-Walter,&nbsp;Rosan Meyer","doi":"10.1111/cea.14557","DOIUrl":"10.1111/cea.14557","url":null,"abstract":"<p>Plant-based diets (PBD) have been reported throughout history, but are increasingly common in current times, likely in part due to considerable emphasis on climate change and human health and wellness. Many dietary organisations around the world endorse well-planned, nutritionally adequate PBD, which exclude some or all forms of animal-based foods. However, special attention must be given to patients who follow PBD and also have food allergy (FA), as avoidance may increase the risk of developing nutritional deficiencies, including poor growth in children, weight loss in adults and vitamin and mineral deficiencies. Given the increasing prevalence of both PBD and food allergen avoidance diets, healthcare providers are likely to counsel patients with FA who also follow a PBD. In this review, an overview of PBD in patients with FA is provided, including recent trends, macro- and micronutrient needs, and growth for children and weight gain considerations for adults. With regard to a PBD, special attention should be given to ensure adequate fat and protein intake and improving the bioavailability of several minerals such as iron, zinc, iodine, calcium and magnesium, and vitamins such as A, B2, B12 and D. Although the collective data on growth amongst children following a PBD are varied in outcome and may be influenced in part by the type of PBD, growth must be regularly monitored and in adults weight gain assessed as part of any clinical assessment in those people with FA.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"895-908"},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14557","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parents' Perspectives on Prevention and Risk Prediction of Food Allergies in Children: A Qualitative Study","authors":"Katharina Gerhardinger,&nbsp;Susanne Brandstetter,&nbsp;Madlen Hörold,&nbsp;Magdalena Rohr,&nbsp;Mara König,&nbsp;Christian Apfelbacher","doi":"10.1111/cea.14569","DOIUrl":"10.1111/cea.14569","url":null,"abstract":"&lt;p&gt;About 6%–8% of children in Western countries develop food allergy (FA) [&lt;span&gt;1&lt;/span&gt;], leading to severe, sometimes life-threatening symptoms. Therefore, predicting the risk of and preventing childhood FA is a significant public health concern. The last decades have seen a paradigm shift in allergy prevention [&lt;span&gt;2&lt;/span&gt;]. As a result, parents are faced with a wide range of sometimes conflicting information and may encounter additional challenges in finding accurate information, especially online [&lt;span&gt;3&lt;/span&gt;]. There is limited qualitative research on childhood FA prevention, as previous studies have focused on the challenges of managing FA [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;As part of the NAMIBIO app consortium [&lt;span&gt;5&lt;/span&gt;], our qualitative study aimed to systematically describe parental information needs and their information seeking behaviour regarding childhood FA risk prediction and prevention. Additionally, we sought to understand parents´ attitudes towards a health app for early risk prediction and prevention of FA in children [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In 2022, KG, MH, MR and CD conducted 30 semi-structured interviews (each 30–60 min), with parents of children up to 3 years of age in Germany. There was no personal relationship between interviewer and interviewees. Interviewees were parents of children diagnosed with FA (&lt;i&gt;n&lt;/i&gt; = 18), at risk of FA (&lt;i&gt;n&lt;/i&gt; = 13), or without known risk factors (&lt;i&gt;n&lt;/i&gt; = 3) [&lt;span&gt;7&lt;/span&gt;]. Using computer-assisted qualitative content analysis [&lt;span&gt;8&lt;/span&gt;], we identified five main (deductive) categories and 15 inductive subcategories [&lt;span&gt;7&lt;/span&gt;]. Transparency and intersubjectivity were ensured through communicative validation in weekly interpretation work sessions. Through reflection and discussion (prior to conducting our study), we were aware of our assumptions about recruitment, participants, target audience and the value of the planned app and were able to integrate these into the reflective interpretive work.&lt;/p&gt;&lt;p&gt;Data analysis (Figure 1) revealed varying parental information needs and degrees of healthcare utilisation regarding FA risk prediction and prevention. Parents' information-seeking behaviour was influenced by different reasons. For one, intuition (‘gut feeling’) strongly motivated parents to address FA issues and seek appropriate healthcare or preventive measures (&lt;i&gt;‘[…] it may sound stupid, but intuitively I googled milk protein allergy at the time […]&lt;/i&gt;', P27, female, early 30s). For another, pre-existing risk awareness (&lt;i&gt;‘Because I have many allergies […]’&lt;/i&gt;, P14, female, late 30s) and occurring symptoms in the child (&lt;i&gt;‘I saw a rash […] and googled it […]’&lt;/i&gt;, P06, female, early 40s) influenced the parents' behaviour. Limited competence in finding valuable information was found to be a barrier to prevention and risk prediction of childhood FA (&lt;i&gt;‘[…] the Internet is big and wide’&lt;/i&gt;, P15, female, mid 30s). Parents' information needs ranged from no interest (&lt;i&gt;","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"943-945"},"PeriodicalIF":6.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor Variation.","authors":"Michael A Portelli, Maria E Ketelaar, Stewart Bates, Eszter Csomor, Dominick Shaw, Jonas Emsley, Christopher Brightling, Ian Hall, Karen Affleck, Matthew Edwards, Martijn C Nawijn, Gerard H Koppelman, Antoon J Van Oosterhout, Ian Sayers","doi":"10.1111/cea.14562","DOIUrl":"https://doi.org/10.1111/cea.14562","url":null,"abstract":"<p><strong>Introduction: </strong>The interleukin-33/interleukin-1 receptor-like-1 (IL-33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway.</p><p><strong>Method: </strong>In a project funded by GSK plc, which has developed an IL-33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa-beta (NF-κB) promoter, were transiently transfected with IL1RL1, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic-generated IL-33 isoforms (0.001-50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin-8 (IL-8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL-33_112-270 (50 ng/mL) and induced IL-8 mRNA expression measured.</p><p><strong>Results: </strong>HEK293 cells carrying both asthma extracellular and TIR domain IL1RL1 risk haplotypes presented maximal IL33-driven signalling, with minimal signalling after IL-33 activation in other protective haplotypes. All IL-33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL33_95-270 and IL33_106-270 had the greatest effect and the IL33_113-270, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes.</p><p><strong>Conclusions: </strong>Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL33_95-270 and IL33_106-270 may be more amenable to IL33/IL1RL1 targeting.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naturally Occurring Food Chemical Components and Extraintestinal and Gastrointestinal Symptoms in Adults: A Systematic Review","authors":"Zoe Cooke,&nbsp;Kathryn Lynam,&nbsp;Caroline Tuck,&nbsp;Gina Louise Trakman","doi":"10.1111/cea.14561","DOIUrl":"10.1111/cea.14561","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic review aims to synthesise existing literature to examine the relationship between natural food chemical components and reported symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>A systematic literature review was completed. Databases CINAHL (Ebscohost), Medline (Ovid), Scopus, Informit Health and Google Scholar were searched to identify relevant articles. The population included human studies of adults (≥17 years) and excluded those with IgE-mediate food allergies. Studies examining food chemical components or ‘food chemical elimination diets’ and symptoms were included. Data was synthesised based on clinical conditions and specific food chemical components examined. The risk of bias was assessed using the Academy of Nutrition and Dietetics ‘Quality Criteria Checklist: Primary Research’.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1659 articles retrieved, 21 met inclusion criteria. This included eight randomised controlled trials, four non-randomised controlled trials, four cohort studies with placebo-controlled challenge, one prospective cohort study, three cross sectional cohort studies, one case–controlled study. Available studies support the role of a low-histamine diet for symptoms in chronic urticaria and low-salicylate diet for reducing sino-nasal symptoms in aspirin exacerbated respiratory disease and chronic rhinosinusitis and/or asthma. While further evidence is needed to verify the role of glutamate in respiratory, pain, asthma and gastrointestinal symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Food chemical elimination diets may improve condition-specific symptoms across the adult cohorts outlined within this review, with the strongest evidence to support the role of a low-histamine diet for management of symptoms in chronic urticaria and a low-salicylate diet in aspirin exacerbated respiratory disease and/or asthma. Further well-designed trials are needed to elucidate the effect of specific natural food chemical components on symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Systematic review number: CRD42022322511.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"855-880"},"PeriodicalIF":6.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14561","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Adult Allergy Action Plan","authors":"Steve Till,&nbsp;Katherine Powrie,&nbsp;Shifa Shaikh","doi":"10.1111/cea.14559","DOIUrl":"https://doi.org/10.1111/cea.14559","url":null,"abstract":"&lt;p&gt;Allergy Action Plans (AAPs) represent an essential tool in management of patients with severe allergies who are at risk of anaphylaxis. Such plans must provide clear and concise guidance on how to recognise and treat severe allergic reactions including anaphylaxis, and should align where possible, with the latest clinical treatment guidelines. Although allergic reactions may occur at any age, historically most AAPs have included information to facilitate recognition by parents or carers of allergic symptoms that are more relevant to children such as ‘change in behaviour’ or becoming ‘floppy’. These plans are not appropriate for adults, for whom self-recognition of symptoms as well as self-administration of adrenaline autoinjectors is far more likely to be needed.&lt;/p&gt;&lt;p&gt;Adults may be exposed to allergens in various settings, such as at work, social gatherings or while travelling. The purpose of an AAP is to provide clear instruction to ensure that adults are prepared to handle allergic reactions promptly and effectively. To do this, the AAP should provide information which enables adults to recognise the symptoms of anaphylaxis so that they know &lt;i&gt;when&lt;/i&gt; to treat an allergic reaction with adrenaline, such as in the event of difficulty breathing or dizziness, and when repeat administration with a second device is necessary [&lt;span&gt;1&lt;/span&gt;]. Conversely, an AAP can help adults differentiate anaphylaxis from mild/moderate allergic reactions that need not require adrenaline, such as hives, or symptoms of a more non-specific nature, such as throat tightness. The plan also advises on additional measures that need to be taken, that is, calling emergency services and mitigating hypotension by lying flat with leg elevation.&lt;/p&gt;&lt;p&gt;A national audit in 2017 by the BSACI Nurses Committee found that 46% of adults prescribed an adrenaline autoinjector were not provided with an accompanying written emergency treatment plan to support its use. One potential reason for this is a lack of access to adult-specific AAPs, including those that are up to date with current anaphylaxis management guidelines as well as being aligned with UK Medicines and Healthcare Products Regulatory Agency (MHRA) recommendations [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;For this reason, the BSACI undertook to develop an open-access Adult AAP in collaboration with national allergy patient charities, Allergy UK and Anaphylaxis UK, with oversight from the BSACI Standards of Care Committee (SOCC).&lt;/p&gt;&lt;p&gt;An initial assessment of existing anaphylaxis plans was undertaken, including those from the American Academy of Allergy, Asthma and Immunology, Australasian Society of Allergy and Clinical Immunology, the BSACI Paediatric Allergy Plans, manufacturer proprietary plans and the latest MHRA guidance on the use of autoinjectors. Following this evaluation, additional elements identified for inclusion were pictorial device-specific instructions, positioning advice and a health professional signature to validate t","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"644-646"},"PeriodicalIF":6.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14559","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.","authors":"Stephanie J Lax, Eleanor Van Vogt, Bridget Candy, Lloyd Steele, Clare Reynolds, Beth Stuart, Roses Parker, Emma Axon, Amanda Roberts, Megan Doyle, Derek K Chu, Masaki Futamura, Miriam Santer, Hywel C Williams, Suzie Cro, Aaron M Drucker, Robert J Boyle","doi":"10.1111/cea.14556","DOIUrl":"https://doi.org/10.1111/cea.14556","url":null,"abstract":"<p><strong>Objective: </strong>Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain.</p><p><strong>Design: </strong>Network meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments.</p><p><strong>Data sources: </strong>Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.</p><p><strong>Eligibility criteria for selected trials: </strong>Included trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory.</p><p><strong>Results: </strong>We identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids.</p><p><strong>Conclusion: </strong>Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional and National Burden of Paediatric Atopic Dermatitis: A Trend and Geographic Inequalities Analysis","authors":"Xueshan Cao,&nbsp;Minmin Wang,&nbsp;Mengge Zhou,&nbsp;Yuanqi Mi,&nbsp;Qi Guo,&nbsp;Yanbin Fan,&nbsp;Yang Guo","doi":"10.1111/cea.14558","DOIUrl":"10.1111/cea.14558","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis (AD) is a common chronic skin disorder in children. We aimed to investigate trends and regional disparities of burden in paediatric AD at global, regional and national levels, and to explore potential associated factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on data from Global Burden of Disease study 2019, we assessed trends in burden of AD aged &lt;19 years from 1990 to 2019, including prevalent and incident cases, age-standardised prevalence and age-standardised incidence. For potential associated factors, correlations of above trends and indexes of socio-economic status (sociodemographic index, SDI) and health service coverage (universal health coverage index, UHCI) were evaluated. We conducted decomposition analysis to understand the net contribution of population-level factors and their contribution proportions on changes of prevalent and incident cases, including age structure, population change and epidemiological change.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Global prevalent and incident cases of paediatric AD increased by about 5.7 and 0.7 million between 1990 and 2019, respectively. Global age-standardised prevalence and incidence decreased by −0.17% (−0.19% to −0.16%) and −0.12% (−0.13% to −0.11%) per year from 1990 to 2019, respectively. Regionally, the highest increase of prevalent and incident cases was in low SDI region (by 96.77% and 84.85%); the highest decrease of age-standardised prevalence and incidence was in high SDI regions (by −0.20% and −0.27% per year). The correlation analyses identified significant negative correlations between trends and SDI and UHCI. Population change was a major driver of case rise; epidemiological change and age structure showed negative impact of case rise. Regional disparities in contribution of three population-level factors were seen, including net contribution direction (positive or negative) and contribution proportion levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Global paediatric AD case numbers increased, primarily due to population growth. Prevalence and incidence decreased slightly. Geographic inequalities were seen. Developing region-specific strategies targeting potential factors is essential to reduce paediatric AD burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 10","pages":"747-759"},"PeriodicalIF":6.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14558","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Pulmonary Rehabilitation on Severe Asthma Outcomes: A Pre-Post Study.","authors":"Émilie Margoline, Emeline Cailliau, Sarah Gephine, Stéphanie Fry, Olivier Le Rouzic, Jean-Marie Grosbois, Cécile Chenivesse","doi":"10.1111/cea.14555","DOIUrl":"https://doi.org/10.1111/cea.14555","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}